A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France
Latest Information Update: 16 Sep 2026
At a glance
- Drugs Avalglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Acronyms PTA Avalglucosidase
- Sponsors Sanofi Genzyme; Sanofi-Aventis Recherche & Developpement
Most Recent Events
- 09 Sep 2026 Planned End Date changed from 30 Sep 2026 to 30 Jun 2027.
- 09 Sep 2026 Planned primary completion date changed from 30 Sep 2026 to 30 Jun 2027.
- 29 Jul 2026 Planned number of patients changed from 18 to 17.